Prime Medicine, Inc. (PRME) Profit Breakdown
- 2026-06-30: Reportable -$42.11M.
- 2025-06-30: Reportable -$52.59M.
Complete filed revenue-to-profit bridge showing gross profit, operating income, pre-tax income and net income.
- Available history
- 2020-12-31 to 2026-06-30
- Data captured
Profit by product
Net Income (Loss) Attributable to Parent: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | -$42.11M |
| 2025-06-30 | -$52.59M |
Nonoperating Income (Expense): each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $1.18M |
| 2025-06-30 | $786.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |